Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Oramed PharmaceuticalsCerecorOvid TherapeuticsGalectoHookipa Pharma
SymbolNASDAQ:ORMPNASDAQ:CERCNASDAQ:OVIDNASDAQ:GLTONASDAQ:HOOK
Price Information
Current Price$9.35$2.51$3.66$5.96$12.35
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score1.31.81.51.61.2
Analysis Score3.53.53.23.53.5
Community Score3.12.92.83.82.6
Dividend Score0.00.00.00.00.0
Ownership Score0.02.50.80.00.0
Earnings & Valuation Score0.00.00.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$16.75$7.50$10.63$14.00$21.14
% Upside from Price Target79.14% upside198.80% upside190.30% upside134.90% upside71.20% upside
Trade Information
Market Cap$282.63 million$223.65 million$240.66 million$150.56 million$320.73 million
Beta1.981.671.86N/A1.18
Average Volume763,877930,7343,573,40633,786176,176
Sales & Book Value
Annual Revenue$2.71 million$6.75 millionN/AN/A$11.94 million
Price / Sales104.2933.13N/AN/A26.86
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.40 per share$0.40 per share$1.46 per shareN/A$5.46 per share
Price / Book6.686.28N/AN/A2.26
Profitability
Net Income$-11,510,000.00$-16,070,000.00$-60,460,000.00N/A$-43,040,000.00
EPS($0.56)($0.30)($1.54)N/A($2.41)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-424.76%-799.40%N/AN/A-232.00%
Return on Equity (ROE)-45.93%-93.78%-140.96%N/A-39.58%
Return on Assets (ROA)-30.33%-61.01%-108.72%N/A-31.33%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.05%
Current Ratio8.93%2.48%5.03%N/A5.65%
Quick Ratio8.93%2.48%5.03%N/A5.65%
Ownership Information
Institutional Ownership Percentage6.03%66.41%39.59%N/A33.39%
Insider Ownership Percentage16.10%58.00%29.80%N/A4.02%
Miscellaneous
EmployeesN/A18652356
Shares Outstanding30.23 million89.11 million65.75 million25.26 million25.97 million
Next Earnings Date7/6/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)7/5/2021 (Estimated)5/13/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
nasdaq.com - April 21 at 5:14 AM
Hookipa Pharma Inc (NASDAQ:HOOK) Expected to Earn Q1 2022 Earnings of ($0.63) Per ShareHookipa Pharma Inc (NASDAQ:HOOK) Expected to Earn Q1 2022 Earnings of ($0.63) Per Share
americanbankingnews.com - April 17 at 3:08 AM
Hookipa Pharma Inc (NASDAQ:HOOK) Expected to Earn Q1 2021 Earnings of ($0.62) Per ShareHookipa Pharma Inc (NASDAQ:HOOK) Expected to Earn Q1 2021 Earnings of ($0.62) Per Share
americanbankingnews.com - April 17 at 1:32 AM
Analysts Issue Forecasts for Hookipa Pharma Incs Q1 2022 Earnings (NASDAQ:HOOK)Analysts Issue Forecasts for Hookipa Pharma Inc's Q1 2022 Earnings (NASDAQ:HOOK)
americanbankingnews.com - April 15 at 7:24 AM
HOOKIPA Pharma to Present at Kempen Life Science ConferenceHOOKIPA Pharma to Present at Kempen Life Science Conference
finance.yahoo.com - April 14 at 9:49 AM
Hookipa Pharma (NASDAQ:HOOK) Receives New Coverage from Analysts at Morgan StanleyHookipa Pharma (NASDAQ:HOOK) Receives New Coverage from Analysts at Morgan Stanley
americanbankingnews.com - April 14 at 9:38 AM
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy ...HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy ...
apnews.com - April 10 at 9:02 AM
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancersHOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
finance.yahoo.com - April 10 at 9:02 AM
Hookipa Pharma (NASDAQ:HOOK) Coverage Initiated at Morgan StanleyHookipa Pharma (NASDAQ:HOOK) Coverage Initiated at Morgan Stanley
americanbankingnews.com - April 8 at 8:16 AM
Hookipa Pharma Inc (NASDAQ:HOOK) Major Shareholder Sells $503,452.43 in StockHookipa Pharma Inc (NASDAQ:HOOK) Major Shareholder Sells $503,452.43 in Stock
americanbankingnews.com - March 31 at 4:50 PM
Sofinnova Capital Vi Fcpr Sells 35,171 Shares of Hookipa Pharma Inc (NASDAQ:HOOK) StockSofinnova Capital Vi Fcpr Sells 35,171 Shares of Hookipa Pharma Inc (NASDAQ:HOOK) Stock
americanbankingnews.com - March 31 at 7:30 AM
Hookipa Pharma Inc (NASDAQ:HOOK) Receives Average Rating of "Buy" from BrokeragesHookipa Pharma Inc (NASDAQ:HOOK) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - March 30 at 5:42 AM
HOOKIPA Pharma: Q4 Earnings InsightsHOOKIPA Pharma: Q4 Earnings Insights
finance.yahoo.com - March 18 at 12:20 PM
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue EstimatesHOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 18 at 12:20 PM
HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 OutlookHOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook
finance.yahoo.com - March 18 at 7:19 AM
HOOKIPA Pharma is about to announce earnings — heres what Wall Street expectsHOOKIPA Pharma is about to announce earnings — here's what Wall Street expects
markets.businessinsider.com - March 16 at 11:50 AM
Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - March 11 at 5:29 PM
HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March ...HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March ...
apnews.com - March 10 at 8:26 AM
HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021
finance.yahoo.com - March 9 at 8:46 AM
Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell ...Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell ...
apnews.com - March 5 at 8:33 PM
Using two different viruses to tackle tumorsUsing two different viruses to tackle tumors
news-medical.net - March 4 at 1:39 PM
Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports MedicinePre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine
finance.yahoo.com - March 4 at 8:38 AM
HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life Sciences ConferenceHOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 3 at 7:34 AM
Did HOOKIPA Pharmas (NASDAQ:HOOK) Share Price Deserve to Gain 19%?Did HOOKIPA Pharma's (NASDAQ:HOOK) Share Price Deserve to Gain 19%?
finance.yahoo.com - February 27 at 2:43 PM
HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare ConferenceHOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 16 at 7:14 AM
DateCompanyBrokerageAction
4/20/2021Oramed PharmaceuticalsCanaccord GenuityInitiated Coverage
2/15/2021Oramed PharmaceuticalsAegisReiterated Rating
2/9/2021Oramed PharmaceuticalsNational SecuritiesInitiated Coverage
12/3/2020Oramed PharmaceuticalsAlliance Global PartnersInitiated Coverage
7/13/2020Oramed PharmaceuticalsHC WainwrightReiterated Rating
9/11/2019Oramed PharmaceuticalsLADENBURG THALM/SH SHInitiated Coverage
7/16/2018Oramed PharmaceuticalsB. RileyDowngrade
4/21/2021CerecorMaxim GroupUpgrade
4/20/2021CerecorJefferies Financial GroupInitiated Coverage
3/21/2021CerecorOppenheimerReiterated Rating
4/20/2021Ovid TherapeuticsCantor FitzgeraldDowngrade
3/4/2021Ovid TherapeuticsUBS GroupBoost Price Target
3/3/2021Ovid TherapeuticsRoyal Bank of CanadaDowngrade
12/2/2020Ovid TherapeuticsSmith Barney CitigroupDowngrade
12/2/2020Ovid TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
12/2/2020Ovid TherapeuticsJMP SecuritiesDowngrade
10/2/2020Ovid TherapeuticsWilliam BlairReiterated Rating
6/18/2020Ovid TherapeuticsPiper SandlerReiterated Rating
3/22/2021GalectoSVB LeerinkLower Price Target
3/22/2021GalectoCredit Suisse GroupLower Price Target
11/23/2020GalectoBank of AmericaInitiated Coverage
4/14/2021Hookipa PharmaMorgan StanleyInitiated Coverage
11/3/2020Hookipa PharmaTruist FinancialInitiated Coverage
(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.